This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. High-throughput flow cytometry is an emerging trend in the flow cytometry market. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate.
While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. In ELISA, colour changes in reagents are used to detect problematic cells. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting "problem cells" in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor. In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics. The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services. Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher and Luminex.
The market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%. The global flow cytometry market is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. DUBLIN-( BUSINESS WIRE)-The "Flow Cytometry Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to 's offering.
0 kommentar(er)
